Completed PHASE2 INTERVENTIONAL 1-arm
NCT06949358
A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France
A Long-Term Follow-up Study to Evaluate Safety and Tolerability of Olipudase Alfa in Patients Who Completed the DFI12712 or the LTS13632 Study in France
Sponsor: Sanofi
Conditions
Niemann-Pick Disease
Interventions
Olipudase alfa
Updated 1 time since 2025 Last updated: Apr 22, 2025 Started: Nov 18, 2021 Primary completion: Apr 8, 2025 Completion: Apr 8, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06949358, this PHASE2 trial focuses on Niemann-Pick Disease and remains completed. Sponsored by Sanofi, it has been updated 1 time since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Completed — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sanofi
Data source: Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .